Fatty liver disease affects approximately 25–30% of the UK population, with growing interest in novel treatments including peptide therapies. Whilst several peptides—particularly GLP-1 receptor agonists such as semaglutide and liraglutide—show promise in research settings for reducing liver fat, none are currently licensed by the MHRA specifically for treating fatty liver disease. Evidence-based management remains centred on lifestyle modification, including weight loss and physical activity, as recommended by NICE guideline NG49. This article examines the current evidence for peptide therapies, their regulatory status in the UK, and essential safety considerations for patients exploring treatment options.

Understanding Fatty Liver Disease and Treatment Options

Fatty liver disease, medically termed hepatic steatosis, occurs when excess fat accumulates in liver cells. The condition exists in two primary forms: non-alcoholic fatty liver disease (NAFLD), affecting individuals who consume little to no alcohol, and alcohol-related liver disease (ARLD), directly related to excessive alcohol intake. NAFLD has become increasingly prevalent in the UK, affecting approximately 25–30% of the general population, often associated with obesity, type 2 diabetes, and metabolic syndrome. (Note: International terminology is evolving towards metabolic dysfunction-associated steatotic liver disease [MASLD] and metabolic dysfunction-associated steatohepatitis [MASH], though NICE guidance currently uses NAFLD and NASH.)

The spectrum of NAFLD ranges from simple steatosis (fat accumulation without inflammation) to non-alcoholic steatohepatitis (NASH), which involves liver inflammation and potential progression to fibrosis, cirrhosis, or hepatocellular carcinoma. Early-stage fatty liver disease typically presents without symptoms, though some patients report fatigue or vague upper abdominal discomfort. Diagnosis usually occurs incidentally through imaging studies such as ultrasound or via risk-based case finding; importantly, liver blood tests (LFTs) may be entirely normal in NAFLD.

Current evidence-based management focuses primarily on lifestyle modification, as recommended by NICE guideline NG49. This includes:

• Gradual weight loss (7–10% of body weight for those who are overweight or obese)

• Regular physical activity (at least 150 minutes of moderate-intensity exercise weekly)

• Dietary improvements, particularly reducing refined carbohydrates and saturated fats

• Management of associated conditions (diabetes, hypertension, dyslipidaemia)

• Alcohol cessation where relevant

Assessment of liver fibrosis is a key component of NICE-recommended care. The FIB-4 score should be used as the initial non-invasive test: in adults under 65 years, a score below 1.3 indicates low risk of advanced fibrosis, whilst a score above 2.67 suggests higher risk; in those aged 65 and over, thresholds are <2.0 (low risk) and >3.25 (higher risk). Intermediate FIB-4 results should prompt an Enhanced Liver Fibrosis (ELF) blood test; an ELF score of 10.51 or above suggests advanced fibrosis and warrants referral to a hepatology service. Referral is also indicated for suspected cirrhosis, diagnostic uncertainty, or concerning features.

Presently, no medications are specifically licensed by the MHRA for treating NAFLD. Under specialist supervision, pioglitazone (a diabetes medication) or vitamin E may be considered in selected adults with biopsy-proven NASH, though both are used off-label for this indication and require careful monitoring for contraindications and adverse effects. The absence of approved pharmacological treatments has led to research interest in various therapeutic approaches, including peptide-based therapies, though these remain investigational and are not part of standard clinical practice in the UK.

Peptides Being Researched for Fatty Liver Disease

Peptides are short chains of amino acids that can influence various biological processes. Several peptide compounds have attracted research attention for potential hepatoprotective properties, though it is crucial to emphasise that none are currently approved for treating fatty liver disease in the UK.

Glucagon-like peptide-1 (GLP-1) receptor agonists represent the most extensively studied peptide class in this context. Medications such as semaglutide (Ozempic for type 2 diabetes; Wegovy for weight management) and liraglutide (Victoza for type 2 diabetes; Saxenda for weight management) are licensed by the MHRA for type 2 diabetes and obesity, with NICE technology appraisals (including TA875 for semaglutide and TA664 for liraglutide) defining NHS access criteria for these indications. These peptides work by enhancing insulin secretion, suppressing glucagon release, slowing gastric emptying, and reducing appetite—mechanisms that collectively promote weight loss and improve metabolic parameters. Research suggests GLP-1 agonists may reduce hepatic steatosis and inflammation, though their primary licensed indications remain diabetes and obesity management, not liver disease.

Fibroblast growth factor 21 (FGF21) analogues are investigational peptides that regulate glucose and lipid metabolism. Early-phase clinical trials have explored synthetic FGF21 variants for their potential to reduce liver fat and improve metabolic health, though these remain in development and are not clinically available.

Other peptides under investigation include thymosin beta-4 and various growth hormone-releasing peptides. However, credible human clinical evidence for these compounds in liver disease is lacking, and they are not approved for any therapeutic use in this context.

It is essential to recognise that research interest does not equate to clinical efficacy or safety. Many peptides promoted online or through unregulated channels lack robust evidence, regulatory approval, or quality assurance. Patients should be extremely cautious about claims regarding 'best' peptides for fatty liver, as such assertions typically lack scientific foundation and may pose health risks.

Evidence for Peptide Therapy in Liver Health

The evidence base for peptide therapy in fatty liver disease varies considerably depending on the specific compound and remains largely investigational rather than established clinical practice.

GLP-1 receptor agonists possess the strongest evidence profile, though primarily as a secondary benefit of their approved indications. Systematic reviews and meta-analyses have demonstrated that GLP-1 agonists significantly reduce liver fat content and improve liver enzyme levels in patients with NAFLD and type 2 diabetes. The magnitude of benefit appears closely related to the degree of weight loss achieved. However, these medications are licensed for diabetes and obesity management, not specifically for liver disease treatment. NICE guidance (NG49) acknowledges their metabolic benefits but does not recommend them solely for NAFLD management outside their approved indications.

Clinical trials examining semaglutide in patients with NASH have shown promising results. A pivotal randomised controlled trial published in the New England Journal of Medicine (2021) demonstrated significant reductions in liver fat and resolution of NASH in some participants receiving semaglutide compared with placebo. However, these remain research findings; semaglutide is not currently licensed by the MHRA for NASH, and histological benefits have not yet led to regulatory approval for this indication. Ongoing phase 3 trials may provide further clarity regarding efficacy, safety, and long-term outcomes in liver-specific populations.

For other peptides, evidence remains considerably more limited. FGF21 analogues have demonstrated liver fat reduction in early-phase trials, but long-term efficacy and safety data are lacking, and no products are near regulatory approval. Thymosin beta-4 and growth hormone-releasing peptides lack robust human clinical evidence for liver disease.

Critical limitations in the current evidence include:

• Most studies focus on surrogate markers (liver fat content, enzyme levels) rather than hard clinical outcomes (cirrhosis prevention, liver-related mortality)

• Long-term safety data beyond 1–2 years are generally unavailable

• Optimal patient selection criteria remain unclear

• Cost-effectiveness has not been established for liver-specific indications

Patients should understand that promising research findings do not constitute proof of clinical benefit or justify off-label use outside properly conducted clinical trials or specialist supervision.

Safety Considerations and Regulatory Status in the UK

The regulatory landscape for peptide therapies in the UK is clear: no peptides are currently licensed by the MHRA specifically for treating fatty liver disease. GLP-1 receptor agonists hold marketing authorisation for type 2 diabetes and obesity but not for NAFLD or NASH as primary indications. Use for liver disease would constitute off-label prescribing, which may be appropriate in certain circumstances under specialist guidance but requires careful consideration of the evidence base and individual patient factors.

Safety considerations associated with peptide therapies vary by compound. GLP-1 receptor agonists, being the most established, have well-characterised adverse effect profiles as detailed in MHRA-approved Summaries of Product Characteristics (SmPCs). Common adverse effects include:

• Gastrointestinal symptoms (nausea, vomiting, diarrhoea), which are very common and affect a substantial proportion of users, particularly during dose escalation

• Gallbladder disorders, including cholelithiasis, associated with rapid weight loss

Warnings and precautions in UK SmPCs include:

• Acute pancreatitis: patients should be advised of characteristic symptoms (persistent severe abdominal pain) and treatment must be discontinued if pancreatitis is suspected

• Diabetic retinopathy complications: in patients with pre-existing diabetic retinopathy, rapid improvement in glucose control has been associated with temporary worsening; careful monitoring is advised

• Pregnancy and breastfeeding: GLP-1 receptor agonists used for weight management (e.g., Wegovy, Saxenda) are contraindicated in pregnancy; women of childbearing potential should use effective contraception

• Renal impairment: caution is required, particularly if gastrointestinal adverse effects lead to dehydration

For investigational peptides, safety profiles remain incompletely characterised, and long-term risks are unknown.

Unregulated peptide products pose significant risks. Online suppliers often market peptides without MHRA approval, quality assurance, or medical supervision. Such products may contain incorrect doses, contaminants, or entirely different substances. The MHRA actively warns against purchasing medicines from unregulated online sources.

Patient safety recommendations include:

• Never purchase peptides from unregulated online sources or unlicensed 'wellness' clinics

• Discuss any interest in peptide therapy with your GP or hepatologist

• Ensure any prescribed peptides are obtained through legitimate NHS or registered pharmacy channels

• Report suspected side effects via the MHRA Yellow Card Scheme at https://yellowcard.mhra.gov.uk/

• Prioritise evidence-based lifestyle modifications as first-line management

Patients experiencing symptoms suggestive of liver disease progression—such as jaundice (yellowing of skin or eyes), abdominal swelling, confusion, or bleeding tendencies—should seek urgent medical attention. Regular monitoring through NHS services, including non-invasive fibrosis assessment as recommended by NICE, remains essential for anyone with diagnosed fatty liver disease, regardless of treatment approach.

Frequently Asked Questions